drugset / Trial / NCT00617747

Efficacy and Tolerability of Zolmitriptan Nasal Spray

NCT00617747

Phase 3 Completed 2114 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches

Timeline

Start
2002-09
Primary completion
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolmitriptan Small molecule 5 mg Intranasal

Indications